MA55021A - 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression - Google Patents

5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Info

Publication number: MA55021A
Authority: MA; Morocco
Prior art keywords: dimethyltryptamine; dmt; meo; depression; methoxy
Prior art date: 2019-02-22

Application number

MA055021A

Other languages

English (en)

Other versions

MA55021B1 (fr

Inventor

Theis Terwey

Original Assignee

Gh Res Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-02-22

Filing date

2020-02-24

Publication date

2021-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-02-24 Application filed by Gh Res Limited filed Critical Gh Res Limited

2021-12-29 Publication of MA55021A publication Critical patent/MA55021A/fr

2024-05-31 Publication of MA55021B1 publication Critical patent/MA55021B1/fr

Links

ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 title 4
208000020401 Depressive disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

MA55021A 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure MA55021B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP19158774		2019-02-22
PCT/EP2020/054803 WO2020169850A1 (fr)	2019-02-22	2020-02-24	5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Publications (2)

Publication Number	Publication Date
MA55021A true MA55021A (fr)	2021-12-29
MA55021B1 MA55021B1 (fr)	2024-05-31

Family

ID=65529503

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA55021A MA55021B1 (fr)	2019-02-22	2020-02-24	5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure

Country Status (32)

Country	Link
US (2)	US20220071958A1 (fr)
EP (3)	EP4353314B1 (fr)
JP (2)	JP7598326B2 (fr)
KR (1)	KR20210154966A (fr)
CN (1)	CN114555078A (fr)
AU (2)	AU2020225410B2 (fr)
BR (1)	BR112021016153A2 (fr)
CA (1)	CA3130406A1 (fr)
CL (1)	CL2021002174A1 (fr)
CO (1)	CO2021010882A2 (fr)
CR (1)	CR20210437A (fr)
DK (3)	DK4353314T3 (fr)
DO (1)	DOP2021000176A (fr)
EA (1)	EA202192318A1 (fr)
EC (1)	ECSP21060868A (fr)
ES (2)	ES2984438T3 (fr)
FI (3)	FI4349407T3 (fr)
HR (2)	HRP20250590T1 (fr)
HU (2)	HUE066828T2 (fr)
IL (1)	IL285537A (fr)
LT (2)	LT3927337T (fr)
MA (1)	MA55021B1 (fr)
MD (1)	MD3927337T2 (fr)
MX (2)	MX2021009941A (fr)
NI (1)	NI202100080A (fr)
PE (1)	PE20220015A1 (fr)
PL (2)	PL4349407T3 (fr)
PT (2)	PT4349407T (fr)
RS (2)	RS66912B1 (fr)
SI (2)	SI3927337T1 (fr)
SM (1)	SMT202400154T1 (fr)
WO (1)	WO2020169850A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
HUE066828T2 (hu)	2019-02-22	2024-09-28	Gh Res Ireland Limited	5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
KR20220008824A (ko)	2019-04-17	2022-01-21	컴퍼스 패쓰파인더 리미티드	실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
GB201907871D0 (en)	2019-06-03	2019-07-17	Small Pharma Ltd	Therapeutic compositions
EP3753923A1 (fr) *	2019-06-19	2020-12-23	GH Research Limited	Récrystallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans de méthyl tert.-butyl éther (mtbe) sans ajouter un antisolvant
HRP20220797T1 (hr)	2019-11-07	2022-10-14	Small Pharma Ltd	Spojevi
EP3868364A1 (fr) *	2020-02-24	2021-08-25	GH Research Limited	Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine
IL297861A (en)	2020-05-08	2023-01-01	Psilera Inc	Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en)	2020-05-19	2026-06-01	Cybin Irl Ltd	Deuterated tryptamine derivatives and methods of use
US12042564B2 (en)	2020-06-02	2024-07-23	Cybin Uk Ltd	Therapeutic solid dosage forms
US11773062B2 (en)	2021-03-22	2023-10-03	Small Pharma Ltd	Deuterated compounds
BR112022025306A2 (pt)	2020-06-12	2023-02-28	Beckley Psytech Ltd	Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
CA3188263A1 (fr) *	2020-08-05	2022-02-10	Matthias Emanuel LIECHTI	Procede d'administration de dmt intraveineux pour psychotherapie assistee par dmt
JP2023539113A (ja)	2020-08-18	2023-09-13	サイビンアイアールエルリミテッド	フェネチルアミン誘導体、組成物およびその使用方法
EP4138818B1 (fr) *	2020-08-28	2024-08-21	Cybin UK Ltd	Formulation injectable
US11406619B2 (en)	2020-08-28	2022-08-09	Small Pharma Ltd	Injectable formulations
EP4221682A2 (fr) *	2020-10-02	2023-08-09	Cybin IRL Limited	Méthodes d'administration de médicaments psychédéliques par inhalation et systèmes de mise en oeuvre des méthodes
CN112138028A (zh) *	2020-10-10	2020-12-29	南京中医药大学	蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (fr) *	2020-10-16	2022-04-21	Eleusis Therapeutics Us, Inc.	Méthode de traitement par alcaloïdes tryptamines
US11660289B2 (en)	2020-12-01	2023-05-30	Small Pharma Ltd.	Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en)	2020-12-01	2026-01-13	Cybin Uk Ltd	Inhalable formulations
EP4255421A1 (fr) *	2020-12-01	2023-10-11	Small Pharma Ltd	Formulations inhalables
US20220265582A1 (en) *	2021-02-24	2022-08-25	Universitätsspital Basel	Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3113414A1 (fr) *	2021-03-29	2022-09-29	Mind Cure Health Inc.	Protocole psychedelique pour systemes et methodes informatiques
US20230136824A1 (en)	2021-04-26	2023-05-04	ATAI Life Sciences AG	N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3216889A1 (fr)	2021-04-26	2022-11-03	Glenn Short	Nouvelles compositions de n,n-dimethyltryptamine et methodes
EP4329759A4 (fr)	2021-04-30	2025-07-16	Mind Medicine Inc	Formes cristallines de sels de lsd
EP4333979A4 (fr) *	2021-05-03	2025-01-15	Mind Medicine, Inc.	Procédé de titrage de doses d'agents psychédéliques
WO2022235927A1 (fr) *	2021-05-05	2022-11-10	Gilgamesh Pharmaceuticals, Inc.	Nouvelles tryptamines et méthodes de traitement de troubles de l'humeur
KR20240013170A (ko)	2021-05-25	2024-01-30	아타이 테라퓨틱스, 인크.	신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en)	2021-06-09	2024-02-01	Atai Therapeutics Inc	Parent drugs and conjugates of dimethyltryptamine
US20230064429A1 (en)	2021-08-19	2023-03-02	Mind Medicine, Inc.	IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US11697638B2 (en)	2021-09-08	2023-07-11	Small Pharma Ltd	5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (fr)	2021-09-30	2023-04-05	Biomind Labs Inc	Nanoparticules encapsulées et nanoparticules de diméthyltriptamines
EP4433049A1 (fr) *	2021-11-18	2024-09-25	Cybin UK Ltd	Formulations injectables et inhalables
US12318477B2 (en)	2021-11-18	2025-06-03	Cybin Uk Ltd	Injectable and inhalable formulations
CA3238440A1 (fr)	2021-12-30	2023-07-06	Atai Therapeutics, Inc.	Analogues de dimethyltryptamine utilises en tant que medicaments d'administration d'oxyde nitrique
WO2023168023A1 (fr)	2022-03-04	2023-09-07	Reset Pharmaceuticals, Inc.	Co-cristaux ou sels comprenant de la psilocine
JP2025510368A (ja)	2022-03-27	2025-04-14	ジーエイチ・リサーチ・アイルランド・リミテッド	不安の処置
KR20250005182A (ko)	2022-03-27	2025-01-09	지에이치 리서치 아일랜드 리미티드	인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
WO2023186834A1 (fr)	2022-03-27	2023-10-05	GH Research Ireland Limited	Sel de bromhydrate cristallin de 5-meo-dmt
GB202212116D0 (en)	2022-08-19	2022-10-05	Beckley Psytech Ltd	Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en)	2022-08-19	2025-04-01	Beckley Psytech Limited	Pharmaceutically acceptable salts and compositions thereof
JP2026505778A (ja)	2023-01-30	2026-02-18	ジーエイチ・リサーチ・アイルランド・リミテッド	産後うつ病の処置における５－ｍｅｏ－ｄｍｔの使用
CN120813348A (zh)	2023-01-30	2025-10-17	Gh研究爱尔兰有限公司	用于治疗产后抑郁的5-甲氧基-n,n-二甲基色胺
GB202306256D0 (en) *	2023-04-27	2023-06-14	Beckley Psytech Ltd	5-Methoxy-N,N-Dimethyltryptamine Formulations
WO2024251807A1 (fr) *	2023-06-08	2024-12-12	Cybin Irl Limited	Traitements d'animaux de compagnie
US12246005B2 (en)	2023-06-13	2025-03-11	Beckley Psytech Limited	5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
EP4784121A1 (fr) *	2023-09-28	2026-08-05	Beckley Psytech Limited	Compositions pharmaceutiques comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
AU2024367931A1 (en)	2023-10-23	2026-02-26	Reconnect Labs Ag	Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
CN122477041A (zh) *	2023-11-22	2026-07-28	吉尔伽美什制药公司	使用n-乙基-2-(5-氟-1h-吲哚-3-基)-n-甲基乙-1-胺或其药学上可接受的盐治疗心境障碍患者
WO2026068951A1 (fr) *	2024-09-27	2026-04-02	Beckley Psytech Limited	5-méthoxy-dmt pour utilisation dans le traitement de la dépression
WO2026078143A1 (fr)	2024-10-09	2026-04-16	GH Research Ireland Limited	Combinaisons de 5-meo-dmt avec des antidépresseurs pour traiter la dépression
WO2026162814A1 (fr)	2025-02-02	2026-08-06	GH Research Ireland Limited	Schémas posologiques à base de mébufoténine pour le traitement du trouble dépressif majeur

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19803376C1 (de)	1998-01-29	1999-10-14	Markus Storz	Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7766013B2 (en)	2001-06-05	2010-08-03	Alexza Pharmaceuticals, Inc.	Aerosol generating method and device
US7458374B2 (en)	2002-05-13	2008-12-02	Alexza Pharmaceuticals, Inc.	Method and apparatus for vaporizing a compound
US20040127409A1 (en)	2002-11-07	2004-07-01	Milkhaus Laboratory, Inc.	Method of treatment of psychological conditions by administration of nerve growth factor
CA2526478A1 (fr)	2003-05-21	2004-12-02	Alexza Pharmaceuticals, Inc.	Procede de regulation thermique uniforme d'un substrat ; unite de chauffage integree et unite d'administration de medicaments recourant a ce procede
DE502006008441D1 (de)	2006-08-01	2011-01-13	Stobi Gmbh & Co Kg	Ventilballon für Inhalatoren
CN103816150A (zh) *	2014-03-14	2014-05-28	兰州理工大学	山蚂蝗生物碱单体成分的用途
US20180021326A1 (en) *	2016-07-23	2018-01-25	Paul Edward Stamets	Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20200147038A1 (en) *	2017-04-20	2020-05-14	Eleusis Benefit Corporation, Pbc	Assessing and treating psychedelic-responsive subjects
US11723894B2 (en) *	2017-10-26	2023-08-15	Terran Biosciences, Inc.	Combination product for the treatment of neurological and/or psychiatric disorders
HUE066828T2 (hu)	2019-02-22	2024-09-28	Gh Res Ireland Limited	5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére

2020
- 2020-02-24 HU HUE20710059A patent/HUE066828T2/hu unknown
- 2020-02-24 EP EP24157388.0A patent/EP4353314B1/fr active Active
- 2020-02-24 HU HUE24157425A patent/HUE071841T2/hu unknown
- 2020-02-24 ES ES20710059T patent/ES2984438T3/es active Active
- 2020-02-24 PT PT241574250T patent/PT4349407T/pt unknown
- 2020-02-24 LT LTEPPCT/EP2020/054803T patent/LT3927337T/lt unknown
- 2020-02-24 HR HRP20250590TT patent/HRP20250590T1/hr unknown
- 2020-02-24 ES ES24157425T patent/ES3031965T3/es active Active
- 2020-02-24 FI FIEP24157425.0T patent/FI4349407T3/fi active
- 2020-02-24 SI SI202030414T patent/SI3927337T1/sl unknown
- 2020-02-24 RS RS20250591A patent/RS66912B1/sr unknown
- 2020-02-24 MX MX2021009941A patent/MX2021009941A/es unknown
- 2020-02-24 SI SI202030619T patent/SI4349407T1/sl unknown
- 2020-02-24 CA CA3130406A patent/CA3130406A1/fr active Pending
- 2020-02-24 PL PL24157425.0T patent/PL4349407T3/pl unknown
- 2020-02-24 FI FIEP20710059.5T patent/FI3927337T3/fi active
- 2020-02-24 US US17/431,626 patent/US20220071958A1/en not_active Abandoned
- 2020-02-24 PL PL20710059.5T patent/PL3927337T3/pl unknown
- 2020-02-24 DK DK24157388.0T patent/DK4353314T3/da active
- 2020-02-24 KR KR1020217030215A patent/KR20210154966A/ko active Pending
- 2020-02-24 SM SM20240154T patent/SMT202400154T1/it unknown
- 2020-02-24 RS RS20240531A patent/RS65706B1/sr unknown
- 2020-02-24 PT PT207100595T patent/PT3927337T/pt unknown
- 2020-02-24 AU AU2020225410A patent/AU2020225410B2/en active Active
- 2020-02-24 MA MA55021A patent/MA55021B1/fr unknown
- 2020-02-24 DK DK24157425.0T patent/DK4349407T3/da active
- 2020-02-24 EA EA202192318A patent/EA202192318A1/ru unknown
- 2020-02-24 LT LTEP24157425.0T patent/LT4349407T/lt unknown
- 2020-02-24 BR BR112021016153-8A patent/BR112021016153A2/pt unknown
- 2020-02-24 MD MDE20211248T patent/MD3927337T2/ro unknown
- 2020-02-24 DK DK20710059.5T patent/DK3927337T3/da active
- 2020-02-24 CR CR20210437A patent/CR20210437A/es unknown
- 2020-02-24 CN CN202080030317.3A patent/CN114555078A/zh active Pending
- 2020-02-24 HR HRP20240532TT patent/HRP20240532T1/hr unknown
- 2020-02-24 EP EP20710059.5A patent/EP3927337B8/fr active Active
- 2020-02-24 WO PCT/EP2020/054803 patent/WO2020169850A1/fr not_active Ceased
- 2020-02-24 PE PE2021001360A patent/PE20220015A1/es unknown
- 2020-02-24 FI FIEP24157388.0T patent/FI4353314T3/fi active
- 2020-02-24 JP JP2021549427A patent/JP7598326B2/ja active Active
- 2020-02-24 EP EP24157425.0A patent/EP4349407B1/fr active Active
2021
- 2021-08-11 IL IL285537A patent/IL285537A/en unknown
- 2021-08-16 CL CL2021002174A patent/CL2021002174A1/es unknown
- 2021-08-17 EC ECSENADI202160868A patent/ECSP21060868A/es unknown
- 2021-08-17 MX MX2025002567A patent/MX2025002567A/es unknown
- 2021-08-18 CO CONC2021/0010882A patent/CO2021010882A2/es unknown
- 2021-08-20 NI NI202100080A patent/NI202100080A/es unknown
- 2021-08-20 DO DO2021000176A patent/DOP2021000176A/es unknown
2024
- 2024-05-28 US US18/675,614 patent/US20240307350A1/en active Pending
- 2024-11-29 JP JP2024208392A patent/JP2025029035A/ja active Pending
2026
- 2026-01-30 AU AU2026200720A patent/AU2026200720A1/en active Pending

Also Published As

Publication number	Publication date
AU2020225410B2 (en)	2025-10-30
WO2020169850A1 (fr)	2020-08-27
EP4353314B1 (fr)	2026-06-24
US20240307350A1 (en)	2024-09-19
PL4349407T3 (pl)	2025-07-21
CR20210437A (es)	2021-11-02
DK4353314T3 (da)	2026-07-13
AU2026200720A1 (en)	2026-02-19
EP4349407B1 (fr)	2025-04-09
CA3130406A1 (fr)	2020-08-27
EA202192318A1 (ru)	2021-12-21
NI202100080A (es)	2021-12-06
ES3031965T3 (en)	2025-07-14
CO2021010882A2 (es)	2022-01-17
DK3927337T3 (da)	2024-04-22
SI3927337T1 (sl)	2024-07-31
EP3927337B1 (fr)	2024-02-14
EP3927337B8 (fr)	2024-03-20
HUE066828T2 (hu)	2024-09-28
RS65706B1 (sr)	2024-08-30
EP4349407A2 (fr)	2024-04-10
JP2025029035A (ja)	2025-03-05
ES2984438T3 (es)	2024-10-29
US20220071958A1 (en)	2022-03-10
PL3927337T3 (pl)	2024-07-29
EP4353314A3 (fr)	2024-07-03
RS66912B1 (sr)	2025-07-31
MX2025002567A (es)	2025-04-02
FI4353314T3 (fi)	2026-07-28
BR112021016153A2 (pt)	2021-10-05
PT3927337T (pt)	2024-05-17
SI4349407T1 (sl)	2025-06-30
PT4349407T (pt)	2025-06-04
ECSP21060868A (es)	2021-11-30
AU2020225410A1 (en)	2021-08-19
LT4349407T (lt)	2025-07-10
HRP20240532T1 (hr)	2024-07-19
JP2022521337A (ja)	2022-04-06
EP3927337A1 (fr)	2021-12-29
MD3927337T2 (ro)	2024-08-31
CN114555078A (zh)	2022-05-27
FI3927337T3 (fi)	2024-05-08
JP7598326B2 (ja)	2024-12-11
DOP2021000176A (es)	2021-11-21
MA55021B1 (fr)	2024-05-31
EP4353314A2 (fr)	2024-04-17
IL285537A (en)	2021-09-30
HUE071841T2 (hu)	2025-09-28
PE20220015A1 (es)	2022-01-11
HRP20250590T1 (hr)	2025-07-04
KR20210154966A (ko)	2021-12-21
SMT202400154T1 (it)	2024-07-09
LT3927337T (lt)	2024-07-10
FI4349407T3 (fi)	2025-06-02
CL2021002174A1 (es)	2022-01-28
MX2021009941A (es)	2021-12-10
EP4349407A3 (fr)	2024-07-03
DK4349407T3 (da)	2025-05-26

Publication	Publication Date	Title
DK4349407T3 (da)	2025-05-26	5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til behandling af svær depression
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
DK3927338T3 (da)	2025-01-06	Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
EP3893940A4 (fr)	2022-09-28	Polythérapie pour le traitement de la dystrophie musculaire
EP3908270A4 (fr)	2022-02-16	Combinaison de dextrométhorphane et de bupropion pour le traitement de la dépression
MA55218A (fr)	2022-01-12	Eskétamine pour le traitement de la dépression
EP3370703A4 (fr)	2019-06-19	Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
PL3658140T3 (pl)	2025-09-08	Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
EP4045037C0 (fr)	2026-01-28	Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3946357A4 (fr)	2023-04-05	Formulations topiques pour le traitement de neuropathies périphériques
EP3335041A4 (fr)	2019-05-15	Biomarqueurs pour le traitement de la pelade
EP3749064A4 (fr)	2021-01-20	Machine de traitement au plasma
EP3634463A4 (fr)	2021-03-17	Protocole amélioré pour le traitement de la néphropathie lupique
EP3405211A4 (fr)	2019-10-09	Octréotide par voie orale pour le traitement de maladies
EP3349793A4 (fr)	2019-05-01	Anti-s100a8 pour le traitement de la leucémie
EP3813738A4 (fr)	2022-04-06	Revêtement nanofibreux pro-régénérateur pro-réparateur pour implants médicaux
EP3960307A4 (fr)	2023-06-21	Liquide de traitement
EP3472320A4 (fr)	2020-04-08	Dysferline tronquée pour le traitement de la dysferlinopathie
MA55531A (fr)	2022-02-09	Procédés pour le traitement de béta-thalassémie
EP3953485A4 (fr)	2023-05-17	Modulation de htra1 pour le traitement de la dmla
EP3630289A4 (fr)	2021-03-03	Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies
MA42419A (fr)	2018-05-16	Méthode de traitement de l'encéphalopathie hépatique
EP3941395A4 (fr)	2022-12-21	Traitement de la cornée
EP4041267A4 (fr)	2024-01-03	Levure pour le traitement de l'allergie
EP3653080A4 (fr)	2021-01-20	Peigne pour le traitement de la pédiculose